BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cetux) +/- chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC)

with No hi ha comentaris
  • Kopetz, S., Grothey, A., Yaeger, R., Ciardiello, F., Desai, J., Kim, T. W., . . . Tabernero, J. (2021). BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cetux) +/- chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS3619 (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *